Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 1.00 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.48 |
| ▸ | ATG7 | O95352 | 5/20 | 0.45 |
| ▸ | NAE1 | Q13564 | 4/20 | 0.43 |
| ▸ | UBA3 | Q8TBC4 | 4/20 | 0.43 |
| ▸ | SAE1 | Q9UBE0 | 3/20 | 0.43 |
| ▸ | UBA2 | Q9UBT2 | 3/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | ABL2 | P42684 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | TEK | Q02763 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18297722 | 0.85 | CA2 (0.74) | CA2ATG7 | |
| SCHEMBL18297534 | 0.79 | CA2 (1.00) | CA2METTL3ATG7NAE1UBA3 | |
| SCHEMBL18297698 | 0.76 | CA2 (0.78) | CA2ATG7 | |
| SCHEMBL18297585 | 0.73 | ADK (0.58) | CA2ABL1EGFRABL2LCK | |
| SCHEMBL23080273 | 0.71 | CA2 (0.55) | CA2ATG7NAE1UBA3 | |
| SCHEMBL1795319 | 0.71 | CA2 (0.55) | CA2ATG7NAE1UBA3 | |
| SCHEMBL30940795 | 0.71 | METTL3 (0.58) | CA2METTL3ABL1EGFRABL2 | |
| SCHEMBL25047789 | 0.71 | METTL3 (0.58) | CA2METTL3ABL1EGFRABL2 | |
| SCHEMBL12566881 | 0.70 | CA2 (0.53) | CA2NAE1UBA3 | |
| SCHEMBL17898107 | 0.69 | ADORA3 (0.60) | CA2NAE1UBA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190010158-A1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND | TAIHO PHARMACETUICAL CO., LTD. (JP) | 2019-01-10 | — | — | US | disclosed |
| US-10174040-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-3395345-A1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-10-31 | — | — | EP | disclosed |
| US-20180162864-A1 | PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF AND COMPOSITIONS CONTAINING THE PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| US-9963456-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD (JP) | 2018-05-08 | — | — | US | disclosed |
| US-20170066772-A1 | NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010158-A1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND | MCL1, TP53, DPYD | CA2 2864/4885METTL3 4259/4885ATG7 4035/4885 |
| US-10174040-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | KRAS, DPYD, PSTPIP2 | CA2 625/4885METTL3 2744/4885ATG7 4283/4885 |
| US-20170066772-A1 | NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT | WASHC5, NME1, NHERF1 | CA2 172/4885METTL3 4039/4885ATG7 4457/4885 |
| US-20180162864-A1 | PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF AND COMPOSITIONS CONTAINING THE PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF | KRAS, DPYD, PSTPIP2 | CA2 625/4885METTL3 2744/4885ATG7 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.